Evidence map›Paper›PMID 37341719›Full record

ReviewUrologie (Heidelberg, Germany)2023

[New forms of immunotherapy in uro-oncology : HLA-independent therapeutic approaches with bispecific antibodies and CAR T cells].

Markus Krebs, Manik Chatterjee, Hubert Kübler, Charis Kalogirou

Abstract readEnglish AbstractReview
PubMed Publisher
In one paragraph

Review in Urologie (Heidelberg, Germany), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 61% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 0 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Markus KrebsKlinik und Poliklinik für Urologie und Kinderurologie, Universitätsklinikum Würzburg, Julius-Maximilians-Universität Würzburg, Oberdürrbacher Str. 6, 97080, Würzburg, Deutschland.
Manik ChatterjeeEarly Clinical Trial Unit (ECTU), Comprehensive Cancer Center Mainfranken, Universitätsklinikum Würzburg, Würzburg, Deutschland.
Hubert KüblerKlinik und Poliklinik für Urologie und Kinderurologie, Universitätsklinikum Würzburg, Julius-Maximilians-Universität Würzburg, Oberdürrbacher Str. 6, 97080, Würzburg, Deutschland.
Charis KalogirouKlinik und Poliklinik für Urologie und Kinderurologie, Universitätsklinikum Würzburg, Julius-Maximilians-Universität Würzburg, Oberdürrbacher Str. 6, 97080, Würzburg, Deutschland. kalogirou_c@ukw.de.
Universitätsklinikum Würzburg · DEUniversity of Würzburg · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immunotherapies using bispecific antibodies and chimeric antigen receptor (CAR) T cells do not depend on previous activation of T cells by the human leukocyte antigen (HLA) system. These HLA-independent approaches displayed groundbreaking clinical results in hematological malignancies-leading to drug approvals for diseases like acute lymphocytic leukemia (ALL), B-cell Non-Hodgkin's lymphoma and multiple myeloma. Currently, several phase I/II trials are investigating the transferability of these results to solid tumors-especially prostate cancer. Compared to established immune checkpoint blockade, bispecific antibodies and CAR T cells have novel and heterogenous side effects such as cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). Treating these side effects and identifying suitable trial participants requires an interdisciplinary treatment approach.

Indexed as

Antibodies, BispecificMultiple MyelomaHistocompatibility AntigensHistocompatibility Antigens Class IIHLA AntigensHumansImmunotherapyImmunotherapy, AdoptiveMaleNeurotoxicity SyndromesReceptors, Antigen, T-CellT-LymphocytesAntibodies, Bispecificcell-associated neurotoxicityHistocompatibility AntigensHistocompatibility Antigens Class IIHLA AntigensReceptors, Antigen, T-CellBispecific antibodiesChimeric antigen receptorClinical phase I/II trialsEarly Clinical Trial UnitProstate cancer

Identifiers

PMID37341719
OpenAlexW4381470670

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.